This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Roche's Rituxan Gets FDA Advisory Committee's Recommendation
by Zacks Equity Research
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.
Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
by Zacks Equity Research
AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA
by Zacks Equity Research
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
by Zacks Equity Research
Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).
Should Value Investors Pick Roche Holding (RHHBY)?
by Zacks Equity Research
Roche Holding (RHHBY) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
How Incyte Stock Became a Bull Market Star for Biotech Investors
by Arpita Dutt
Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.
Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
by Zacks Equity Research
Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.
Can Epizyme (EPZM) Spring a Surprise This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) is scheduled to report fourth-quarter 2016 results on Mar 9, before the opening bell.
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
5 FDA Decisions to Watch Out for in Mar 2017
by Arpita Dutt
Companies like Merck (MRK) are awaiting key FDA decisions this month.
What's in Store for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug
by Arpita Dutt
Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.
Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View
by Zacks Equity Research
Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.
Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.
Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
by Zacks Equity Research
Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
by Zacks Equity Research
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.
Prothena (PRTA) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
Prothena's wider-than-expected loss in the fourth quarter was disappointing.
Can Prothena (PRTA) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.
Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat
by Kinjel Shah
Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.
Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo
Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales
by Zacks Equity Research
Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.